Disease-specific survival of type I and type II epithelial ovarian cancers—stage challenges categorical assignments of indolence & aggressiveness

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Epithelial ovarian cancers (EOC) consist of several sub-types based on histology, clinical, molecular and epidemiological features that are termed “histo-types”, which can be categorized into less aggressive Type I and more aggressive Type II malignancies. This investigation evaluated the disease-specific survival (DSS) of women with Type I and II EOC using histo-type, grade, and stage. A total of 47,789 EOC cases were identified in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) data. Survival analysis and log rank test were performed to identify a 2-tiered classification (grade 1 vs. grade 2 & 3) for serous EOC. DSS of early stage serous EOC for grade 2 was significantly different from grade 3 indicating that a 2-tier classification for serous EOC applied only to late stage. DSS of Type I EOC was much better than Type II. However, DSS was 33–52% lower with late stage Type I than with early stage Type I indicating that Type I ovarian cancers should not be considered indolent. Early stage Type II EOC had much better DSS than late stage Type II stressing that stage has a large role in survival of both Type I and II EOC.

Original languageEnglish
Article number56
JournalDiagnostics
Volume10
Issue number2
DOIs
StatePublished - 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Epithelial ovarian cancer
  • Grade
  • Histo-types
  • Stage
  • Survival
  • Type I & Type II

ASJC Scopus subject areas

  • Internal Medicine
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Disease-specific survival of type I and type II epithelial ovarian cancers—stage challenges categorical assignments of indolence & aggressiveness'. Together they form a unique fingerprint.

Cite this